20 percent more patients were treated with proton therapy in 2019
An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB
Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt
For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany.
500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.
To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.
Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB.
- Magnetic field during catalyst synthesis triples ammonia yieldApplying an external magnetic field during the synthesis of CoFe₂O₄ electrocatalysts triples the ammonia yield during electrocatalytic conversion. The magnetic field alters the surface states of the spinel oxide thin films, making catalytically active sites more accessible. In the journal 'Advanced Functional Materials', a team led by Marcel Risch at HZB and Sanjay Mathur at University of Cologne demonstrates a scalable strategy for developing next-generation electrocatalysts for efficient and sustainable chemical production.
- Imaging Ellipsometry for Process Control of Thin-Film DevicesA German–Israeli research team led by Dr. Andreas Furchner has demonstrated how imaging ellipsometry enables non-destructive characterisation and quality control of microstructured MXene thin films during device fabrication. The authors used two complementary ellipsometry approaches for precise, multi-scale access to key material properties. The work positions imaging ellipsometry as a powerful platform for monitoring thin-film uniformity, device integrity, and functionality throughout processing, including critical lithographic steps. The study was published in Applied Physics Letters and selected as an Editor’s Pick.
- Cool vaccines in rural Kenya: solar solution has been awarded by UNIn May 2026, Tabitha Awuor Amollo is spending some weeks as a guest scientist at HZB, analysing perovskite thin films at BESSY II. The Kenyan physicist from Egerton University, Nairobi, was recently recognised for her achievements in research and teaching. For the development of a solar-powered refrigeration system for use in rural health centres, she has been awarded the 2026 Organization for Women in Science for the Developing World (OWSD)-Elsevier Foundation Award. An interview on exceptional projects and daily struggles of a scientist. Questions were asked by Antonia Rötger.